Targeted Diagnostics for Brain Health


DiamiR Announces Research Collaboration With Johnson & Johnson Innovation

MONMOUTH JUNCTION, NJ--(Marketwired - January 11, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Johnson & Johnson Innovation facilitated the agreement.

DiamiR has developed a proprietary targeted approach for early detection and monitoring of neurodegenerative diseases based on quantitative analysis of brain-enriched microRNA pairs in plasma. In this collaboration, DiamiR and Janssen Neuroscience teams will jointly investigate how DiamiR technology can be used in the context of clinical development of a therapeutic agent for treatment of neurodegenerative disease indications.
DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease

MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR a Small Business Innovation Research (SBIR) grant to support further validation and development of the company's targeted diagnostic technology based on the analysis of brain-enriched microRNA biomarkers in plasma for early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). 

Read more


DiamiR Announces Publication and Discusses Merits of Universal Screening Test Based on Organ-Enriched microRNA Signatures


MONMOUTH JUNCTION, NJ--(Marketwired - November 03, 2014) - DiamiR Biosciences Corp., a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today the publication entitled " Universal Screening Test based on analysis of circulating organ-enriched microRNAs: a novel approach to diagnostic screening" in Expert Reviews of Molecular Diagnostics [http://dx.doi.org/10.1586/14737159.2014.973858].

Read more



DiamiR Announces Grant From The Michael J. Fox Foundation for Parkinson's Research to Advance Assessment of Brain-Enriched microRNA Biomarkers in Plasma


MONMOUTH JUNCTION, NJ--(Marketwired - July 14, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the award of a grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant will support a validation study of brain-enriched microRNA biomarker pairs for detection of Parkinson's disease using plasma samples of Parkinson's patients and age-matched controls from the BioFIND clinical study, sponsored by MJFF and supported by the National Institute of Neurological Disorders and Stroke. Further information can be found at: https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1347

Read more















DiamiR Granted Key US Patent for the Use of Circulating Brain-Enriched microRNAs for Early Detection of Neurodegeneration

MONMOUTH JUNCTION, NJ--(Marketwired - February 12, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,648,017, entitled "Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases." The patent, which is set to expire in November 2030, claims the use of methods developed by DiamiR for early detection and diagnosis of neurodegenerative diseases.

Read more



DiamiR Reports Validation of Two Families of Brain-Enriched microRNAs as Highly Promising Blood-Based Biomarkers of Mild Cognitive Impairment

MONMOUTH JUNCTION, NJ--(Marketwired - January 02, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based tests for detection and monitoring of neurodegenerative diseases and cancer, announced today the publication entitled "Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study" in Aging. Mild Cognitive Impairment is a condition characteristic of early stages of many neurodegenerative diseases, including Alzheimer's disease. The article can be accessed online at http://www.impactaging.com/papers/v5/n12/abs/100624a.html.

Contact:                                                                                                                                                                    SIGN UP FOR UPDATES HERE 
DiamiR

11 Deer Park Drive, Suite 102G
Monmouth Junction, NJ 08852
Email: info@diamirbio.com